# Report: 01_OPC-AC-like_1 (run_2.md)

**Cell type:** malignant glioblastoma cell
**Disease:** glioblastoma
**Tissue:** brain

## Program Summaries
### Mesenchymal Invasion and ECM Remodeling
Co-activation of genes encoding ECM receptors and remodeling proteins (CD44, ITGB4, ADAMTS5, PLA2G4A, COL20A1, CHST8, XYLT1, GPC5, TNR) promote invasive, mesenchymal state and facilitate glioblastoma cell migration through the brain parenchyma. Many are upregulated in GBM with mesenchymal phenotype, linked to recurrent tumors and poor prognosis.

**Predicted impacts:**
- Enhanced migratory capacity and brain infiltration
- Therapy resistance via ECM protection
- Recurrence after surgical resection

**Supporting genes:** CD44, ITGB4, PLA2G4A, ADAMTS5, COL20A1, CHST8, XYLT1, GPC5, TNR

**References:** [162], [17]

**Biological processes:**
- ECM remodeling and invasion: CD44, ITGB4, PLA2G4A, COL20A1, CHST8, XYLT1, GPC5, TNR, ADAMTS5 (refs: [17], [162])

**Cellular components:**
- Extracellular matrix, focal adhesion, invadopodia: CD44, ITGB4, TNR, COL20A1 (refs: [17])

**Reference notes:**
- Comprehensive review evidencing ECM gene upregulation in GBM.
- CD44 role in GBM invasion and recurrence.

### Cancer Stemness, Plasticity, and Therapy Resistance
Markers of stem cell phenotype (GFAP, CD44, SLC7A11, GPC5, LUCAT1, PPARGC1A) and key regulatory lncRNAs enable glioblastoma cells to maintain stem-like state, resist differentiation, and survive stressors including hypoxia and chemotherapy.

**Predicted impacts:**
- Maintains cell population capable of recurrence after therapy
- Resistance to chemoradiation
- Adaptation to hypoxic, nutrient-poor microenvironments

**Supporting genes:** GFAP, CD44, SLC7A11, GPC5, LUCAT1, PPARGC1A

**References:** [151], [6]

**Biological processes:**
- Stem cell maintenance and chemoresistance: GFAP, CD44, SLC7A11, PPARGC1A (refs: [6])
- Hypoxia-responsive regulation: LUCAT1, PPARGC1A (refs: [151])

**Cellular components:**
- Cancer stem cell niche: GFAP, CD44 (refs: [6])

**Reference notes:**
- Role of stem cells in GBM therapy resistance.
- LUCAT1 function in hypoxia response in glioblastoma.

### Immune Evasion and Immune Microenvironment Interaction
NLRC5, SLC7A11, and lncRNAs interact to modulate antigen presentation and redox state in glioblastoma, facilitating immune escape. Additional ECM–related genes assist in constructing immunosuppressive niches.

**Predicted impacts:**
- Evades T cell recognition
- Promotes redox homeostasis and resistance to immune cell mediated killing
- Maintains local immunosuppressive microenvironment

**Supporting genes:** NLRC5, SLC7A11

**References:** [13], [34]

**Biological processes:**
- MHC class I antigen presentation: NLRC5 (refs: [34])
- Suppression of ferroptosis and redox modulation: SLC7A11 (refs: [13])

**Cellular components:**
- Immune suppressive microenvironment: NLRC5, SLC7A11 (refs: [41])

**Reference notes:**
- NLRC5 as central regulator of MHC class I.
- SLC7A11 axes and ferroptosis–immune crosstalk in GBM.

### Proliferation and Aberrant Cell Cycle Regulation
PPARGC1A, KCNIP1, INPP4B, PLA2G4A, CD44, and specific lncRNAs (e.g., LUCAT1) coordinate metabolic and cell cycle programs to support high proliferative rates of glioblastoma cells.

**Predicted impacts:**
- Increased proliferation and metabolic flexibility
- Survival under nutrient and hypoxia stress
- Therapy resistance through metabolic adaptation

**Supporting genes:** PPARGC1A, KCNIP1, INPP4B, PLA2G4A, CD44, LUCAT1

**References:** [127], [191]

**Biological processes:**
- Mitochondrial biogenesis and metabolism: PPARGC1A (refs: [191])
- PI3K/AKT signaling modulation: INPP4B (refs: [127])

**Cellular components:**
- Mitochondria, cytoplasm: PPARGC1A (refs: [191])

**Reference notes:**
- PGC1α and metabolic adaptation in cancer invasion.
- PI3K/AKT pathway regulation by INPP4B in GBM.

### Aberrant Neural and Synaptic Programs
Genes encoding cell adhesion molecules, synaptic scaffolding proteins, and neural developmental regulators (UNC5D, LRRC4C, MDGA2, ARC, KCNIP1, ST8SIA1, ST8SIA5) are often upregulated in glioblastoma, supporting tumor-neuronal communication, invasion, and plasticity.

**Predicted impacts:**
- Enhanced tumor–neuron electrical coupling
- Network remodeling favoring tumor invasion
- Synaptic plasticity supporting proliferation and migration

**Supporting genes:** ARC, MDGA2, ST8SIA1, ST8SIA5, UNC5D

**References:** [170]

**Biological processes:**
- Neuronal–glioma synaptic remodeling: ARC, ST8SIA1, ST8SIA5, UNC5D, MDGA2 (refs: [170])

**Cellular components:**
- Synaptic junctions, neural cell adhesion complexes: ARC, MDGA2, ST8SIA1, ST8SIA5, UNC5D (refs: [170])

**Reference notes:**
- Role of glioma synapses in cell network remodeling.

## GO Comparison
| Program | Similar GO term(s) | Novel aspects |
| --- | --- | --- |
| Glial/astrocyte differentiation and tumor plasticity | nan | Identifies lineage plasticity and astrocyte lineage transitions supported by neural activity genes (ARC, DAB1) not directly reflected in glycoprotein biosynthesis. |
| Mesenchymal invasion and matrix remodeling | glycoprotein biosynthetic process (GO:0009101) | Explicitly details cell-matrix adhesion via integrins (ITGB4), CD44, metalloproteinases (ADAMTS5), ECM proteins, and pro-migratory lipid signaling (PLA2G4A). |
| Redox and ferroptosis resistance | nan | Links SLC7A11 (xCT) and LUCAT1 to ROS/ferroptosis resistance and metabolic adaptation, a program not captured by glycoprotein biosynthetic process. |
| Immune evasion: MHC class I downregulation | nan | Focuses on NLRC5-mediated antigen presentation and immune evasion, an axis not covered by glycoprotein synthesis. |

## References
- [127] https://pubmed.ncbi.nlm.nih.gov/35330704; Notes: PI3K/AKT pathway regulation by INPP4B in GBM. | INPP4B tumor suppressor role, inhibits GBM cell proliferation via PI3K/AKT axis.
- [13] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484322/; Notes: SLC7A11 axes and ferroptosis–immune crosstalk in GBM. | SLC7A11 as ferroptosis inhibitor in cancer, including GBM.
- [151] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11001947/; Notes: LUCAT1 function in hypoxia response in glioblastoma. | LUCAT1 and hypoxia response in GBM.
- [162] https://pubmed.ncbi.nlm.nih.gov/37784103; Notes: CD44 role in GBM invasion and recurrence. | CD44-driven GBM invasion.
- [17] https://www.mdpi.com/1422-0067/24/5/4891; Notes: Comprehensive review evidencing ECM gene upregulation in GBM. | Systematic review of glioblastoma ECM modification and invasion. | Detailed structure of ECM in glioblastoma.
- [170] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611371/; Notes: Role of glioma synapses in cell network remodeling. | Glioma synapses and adaptive plasticity mechanisms in GBM. | Synaptic network architecture in glioma.
- [191] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920288/; Notes: PGC1α and metabolic adaptation in cancer invasion. | PGC1α drives OXPHOS and metabolic adaptation in invasive and metastatic cancer. | PGC1α required for metastatic phenotype via mitochondrial adaptation.
- [34] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919433/; Notes: NLRC5 as central regulator of MHC class I. | NLRC5 function as MHC class I transactivator.
- [41] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684490/; Notes: Epigenetic and metabolic barriers to immune attack in GBM.
- [6] https://pmc.ncbi.nlm.nih.gov/pmc/articles/PMC9481599/; Notes: Role of stem cells in GBM therapy resistance. | Glioma stem cell involvement in therapy resistance. | GBM stem cell niche and therapy resistance.
